There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Annexon Biosciences (ANNX – Research Report) and Geron (GERN – Research Report) with bullish sentiments.
Annexon Biosciences (ANNX)
Needham analyst Joseph Stringer maintained a Buy rating on Annexon Biosciences today and set a price target of $16.00. The company’s shares closed last Friday at $5.97, close to its 52-week high of $6.67.
According to TipRanks.com, Stringer is a 3-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Annexon Biosciences with a $14.80 average price target, which is a 138.7% upside from current levels. In a report issued on March 1, J.P. Morgan also upgraded the stock to Buy with a $11.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Geron (GERN)
Needham analyst Gil Blum maintained a Buy rating on Geron today and set a price target of $4.00. The company’s shares closed last Friday at $2.26.
According to TipRanks.com, Blum is a 4-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Geron with a $4.90 average price target, a 141.4% upside from current levels. In a report issued on February 28, Goldman Sachs also maintained a Buy rating on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on ANNX:
